OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Oct 09
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Biotech Industry Analysis
UpdatedOct 12, 2024
DataAggregated Company Financials
Companies114
- 7D4.0%
- 3M11.5%
- 1Y49.5%
- YTDn/a
In the last week, the Biotech industry is up 4.3%, with ALTEOGEN up 8.4%. During this same period, the HLB TherapeuticsLtd underperformed, falling 14%. In the last 12 months, the industry was up 44%. Looking forward, earnings are forecast to grow by 65% annually.
Industry Valuation and Performance
Has the South Korean Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 13 Oct 2024 | ₩98.5t | ₩10.3t | -₩653,791,712,887.00 | 26.2x | -150.7x | 9.5x |
| Tue, 10 Sep 2024 | ₩89.9t | ₩10.3t | -₩664,461,088,267.00 | 24x | -135.2x | 8.7x |
| Thu, 08 Aug 2024 | ₩91.0t | ₩9.9t | -₩651,620,427,048.00 | 23.2x | -139.6x | 9.2x |
| Sat, 06 Jul 2024 | ₩85.9t | ₩9.9t | -₩651,620,427,048.00 | 22x | -131.9x | 8.7x |
| Mon, 03 Jun 2024 | ₩78.2t | ₩9.9t | -₩651,185,661,208.00 | 20.3x | -120.1x | 7.9x |
| Wed, 01 May 2024 | ₩82.1t | ₩9.6t | -₩574,854,220,678.00 | 22.3x | -142.7x | 8.5x |
| Fri, 29 Mar 2024 | ₩83.8t | ₩9.5t | -₩596,335,654,327.00 | 23.3x | -140.5x | 8.8x |
| Sun, 25 Feb 2024 | ₩77.3t | ₩9.7t | -₩534,696,541,747.00 | 62.7x | -144.5x | 7.9x |
| Tue, 23 Jan 2024 | ₩74.3t | ₩9.7t | -₩537,261,689,777.00 | 63.4x | -138.3x | 7.6x |
| Thu, 21 Dec 2023 | ₩62.5t | ₩10.1t | -₩311,749,314,637.00 | 28.5x | -200.4x | 6.2x |
| Sat, 18 Nov 2023 | ₩57.8t | ₩10.2t | -₩268,639,297,229.00 | 28.3x | -215.2x | 5.7x |
| Mon, 16 Oct 2023 | ₩54.7t | ₩10.2t | -₩239,053,318,689.00 | 28x | -229x | 5.4x |
| Wed, 13 Sep 2023 | ₩59.8t | ₩10.2t | -₩338,340,868,849.00 | 33.2x | -176.7x | 5.9x |
| Fri, 11 Aug 2023 | ₩60.7t | ₩10.3t | -₩166,675,753,149.00 | 32.1x | -364.5x | 5.9x |
| Sun, 09 Jul 2023 | ₩55.4t | ₩10.3t | -₩151,534,704,579.00 | 26.5x | -365.3x | 5.4x |
| Tue, 06 Jun 2023 | ₩63.5t | ₩10.3t | -₩151,338,675,579.00 | 31.2x | -419.4x | 6.2x |
| Thu, 04 May 2023 | ₩60.4t | ₩11.0t | ₩317.9b | 24.1x | 190x | 5.5x |
| Sat, 01 Apr 2023 | ₩57.4t | ₩11.0t | ₩319.9b | 23.6x | 179.5x | 5.2x |
| Mon, 27 Feb 2023 | ₩57.2t | ₩11.3t | ₩968.6b | 24.7x | 59.1x | 5.1x |
| Wed, 25 Jan 2023 | ₩58.7t | ₩11.3t | ₩970.8b | 24.1x | 60.4x | 5.2x |
| Fri, 23 Dec 2022 | ₩62.7t | ₩10.8t | ₩213.8b | 26.2x | 293.4x | 5.8x |
| Sun, 20 Nov 2022 | ₩62.6t | ₩11.1t | ₩376.8b | 20.5x | 166.1x | 5.7x |
| Tue, 18 Oct 2022 | ₩57.3t | ₩10.8t | ₩348.0b | 20.4x | 164.7x | 5.3x |
| Thu, 15 Sep 2022 | ₩64.4t | ₩10.8t | ₩495.4b | 23.6x | 130x | 5.9x |
| Sat, 13 Aug 2022 | ₩74.4t | ₩10.7t | ₩597.2b | 26.8x | 124.5x | 7x |
| Mon, 11 Jul 2022 | ₩69.1t | ₩10.7t | ₩597.6b | 24x | 115.6x | 6.5x |
| Wed, 08 Jun 2022 | ₩66.5t | ₩10.6t | ₩622.0b | 27.6x | 106.9x | 6.3x |
| Fri, 06 May 2022 | ₩69.6t | ₩10.0t | ₩866.3b | 27.2x | 80.4x | 7x |
| Sun, 03 Apr 2022 | ₩75.2t | ₩9.9t | ₩866.6b | 25.4x | 86.8x | 7.6x |
| Tue, 01 Mar 2022 | ₩71.2t | ₩9.4t | ₩783.3b | 33.6x | 90.9x | 7.6x |
| Thu, 27 Jan 2022 | ₩73.8t | ₩9.4t | ₩787.4b | 32.8x | 93.7x | 7.9x |
| Sat, 25 Dec 2021 | ₩91.7t | ₩9.4t | ₩787.4b | 39.3x | 116.5x | 9.8x |
| Mon, 22 Nov 2021 | ₩95.5t | ₩9.2t | ₩1.0t | 43.1x | 91.2x | 10.4x |
| Wed, 20 Oct 2021 | ₩98.2t | ₩9.2t | ₩986.0b | 39.7x | 99.6x | 10.7x |
Price to Earnings Ratio
99.6x
Current Industry PE
- Investors are optimistic on the South Korean Biotechnology industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 7.0x is lower than the industry's current PS ratio of 9.3x.
Past Earnings Growth
- Total earnings for the Biotechnology industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 3.9% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does South Korean Biotech compare with similar industries?
| KR Market | 0.87% | |
| Healthcare | 2.79% | |
| Biotech | 4.03% | |
| Biotech | 4.03% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A196170 ALTEOGEN | ₩386.00k | 8.4% +₩1.6t | 527.6% | PS225.9x | |
| A068270 Celltrion | ₩197.30k | 2.4% +₩949.2b | 37.1% | PE125.9x | |
| A298380 ABL Bio | ₩40.50k | 24.6% +₩384.4b | 105.1% | PS59x | |
| A950160 Kolon TissueGene | ₩16.91k | 22.2% +₩244.0b | 97.8% | n/a | |
| A226950 OliX Pharmaceuticals | ₩26.90k | 55.2% +₩165.4b | 67.4% | PS25.7x |
